Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.6952W HIGH $34.48
Volume
5.43 M
Value Traded
184.38 M
Short % Float
7.07%
+10.07%Week
-0.3%1 Month
+5.48%3 Month
+126.34%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.16 B
EPS (TTM)
1.78
P/E Ratio
18.44
Ent. Value
432.85 M
Total Shares
308.64 M
Float Shares
251.46 M
Insiders
18.54%
Institutions
61.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
OSCR Catalyst Timeline
Dated clinical, regulatory and corporate events for Oscar Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oscar Health, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How OSCR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Oscar Health, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every OSCR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WITTMAN VANESSA AMESDirector | Sell | -25,000 112,121 held | $32.24 | 09/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OSCR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 1.3 % (160 %) | 14.80 M | 519.02 K | 3.84% ( 19.18 K) |
OSCR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OSCR ranks across every disease it competes in
Competitive Position is a premium feature
See how OSCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOSCR News
-OSCR
Sep 19, 2026Oscar Health Announces Thrive Capital’s Completion of Oscar Health Common Stock Distribution to its Limited Partners
Oscar Health announced the completion of a stock distribution by Thrive Capital, its majority stockholder. On September 18, 2026, Thrive Capital distributed approximately 6.3 million shares of Oscar Health Class A common stock to its limited partners. This move is designed to return capital to Thrive Capital's limited partners.
Read more →-OSCR
Aug 6, 2026▼ -11.9%on this news
Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook
Oscar Health reported strong financial results for the second quarter of 2026, showcasing significant improvements compared to the previous year. The company has raised its outlook for the full year 2026, indicating confidence in continued growth. All core metrics demonstrated positive trends, reflecting the company's robust performance.
Read more →-OSCR
Jul 13, 2026Oscar Health, Inc. 2026 Second Quarter Earnings Conference Call
Oscar Health, Inc. is set to announce its financial results for the second quarter of 2026 on August 6, 2026. This release is part of the company's regular reporting schedule. Investors and analysts will be keen to assess the company's performance during this period.
Read more →-OSCR
Apr 20, 2026Meet Lucie. A New Way to Shop for Healthcare.
The article introduces a new healthcare shopping platform named Lucie. It emphasizes the platform's focus on privacy and protection for users. However, specific details about its features or benefits are not provided.
Read more →-OSCR
Jan 13, 2026Oscar Health, Inc. 2025 Fourth Quarter and Full Year Earnings Conference Call
Oscar Health, Inc. will announce its fourth quarter and full year 2025 financial results on February 10, 2026. A conference call will follow at 8:00 AM ET to discuss these results. The call will be archived for 90 days on the company's investor relations website. Oscar Health continues to focus on technology-driven healthcare solutions.
Read more →-OSCR
Sep 16, 2025Oscar Health Prices Upsized
Oscar Health, Inc. has priced its upsized offering of $355 million in convertible senior subordinated notes, intended to bolster long-term growth and market adoption. The offering's net proceeds, estimated at approximately $342.5 million, will be used for corporate purposes and strategic initiatives. Notably, Oscar aims to enhance consumer healthcare experiences while pursuing opportunities related to premium tax credits.
Read more →-OSCR
Sep 15, 2025Oscar Health Launches Proposed Convertible Senior Subordinated Notes Offering to Scale Long-Term Growth and Consumer and Employer Adoption of the Individual Market
Oscar Health, Inc. has announced a proposed offering of $350 million in convertible senior subordinated notes, intending to use the proceeds for general corporate purposes and strategic growth initiatives. This initiative aims to enhance consumer healthcare experiences through advancements in AI and potentially extend premium tax credits. The company also plans to settle conversions with cash or shares of its common stock. The notes will be unsecured and subject to various conditions that could affect their performance and the company’s stock price.
Read more →-OSCR
Nov 20, 2023▲ +8.8%on this news
Oscar Health, Inc. ir.hioscar.com News Release Oscar Health, Inc. Announces that Mark Bertolini s Foundation and Deerfield Management have Entered into an Agreement with a Selling Shareholder to Purchase Shares of Oscar
Oscar Health, Inc. announced a Stock Purchase Agreement where Deerfield Management and the Anahata Foundation will purchase shares of its Common Stock. Deerfield is to acquire 3 million shares while Anahata will buy 2 million shares. The transactions are scheduled to close around November 22, 2023, pending customary conditions. Oscar is not a party to these agreements but benefits from the endorsement and financial backing of these investors.
Read more →-OSCR
Jan 27, 2022Oscar Health, Inc. ir.hioscar.com News Release Oscar Health Delivers Historic Growth, Issues Guidance for 2022 of More than $6B in Premiums Total enrollment for 2022 tops one million members across the Oscar platform Pro
Oscar Health Delivers Historic Growth, Issues Guidance for 2022 of More than $6B in Premiums NEW YORK, New York, January 27, 2022 Oscar Health, Inc. ( Oscar or the Company ) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, today issued
Read more →About Oscar Health, Inc.
Headquarters75 VARICK STREET, NEW YORK, NY, 10013
BIOPHARMAWATCH ELITE PLUS
Trade the next OSCR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime